Skip to main content

Emmaus Life Sciences, Inc. (EMMA)

OTCMKTS: EMMA · IEX Real-Time Price · USD
1.70 -0.03 (-1.73%)
Sep 23, 2021 3:48 PM EDT - Market closed
Market Cap83.83M
Revenue (ttm)23.68M
Net Income (ttm)n/a
Shares Out49.31M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume35,742
Open1.75
Previous Close1.73
Day's Range1.40 - 1.75
52-Week Range0.70 - 1.85
Beta1.34
Analystsn/a
Price Target24.00 (+1,311.8%)
Est. Earnings Daten/a

About EMMA

Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Emmaus Life Sciences, Inc. has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer dr...

IndustryPharmaceuticals
Founded2000
CEOYutaka Niihara
Employees56
Stock ExchangeOTCMKTS
Ticker SymbolEMMA
Full Company Profile

Financial Performance

Financial Statements

News

OTC Markets Group Welcomes Emmaus Life Sciences, Inc. to OTCQX

NEW YORK, Sept. 8, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA...

2 weeks ago - PRNewsWire

3 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:FTK
3 weeks ago - Benzinga

Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021

TORRANCE, Calif., Sept. 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced f...

3 weeks ago - PRNewsWire

Emmaus Life Sciences Announces Bahrain Temporary License of Endari®

TORRANCE, Calif. , Aug. 17, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today ...

1 month ago - PRNewsWire

Emmaus Life Sciences Provides SEC Reporting Update

TORRANCE, Calif., Aug. 10, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that it has restated its financial statements for the f...

1 month ago - PRNewsWire

3 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:AMHGMBIO
1 month ago - Benzinga

Texas Adds Endari® to Latest Preferred Drug List

TORRANCE, Calif., Aug. 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that Endari® has been included on the Preferred D...

1 month ago - PRNewsWire

Emmaus Life Sciences Provides Interim Sales Information

TORRANCE, Calif., July 22, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today preliminary sales results for the six months ended June...

2 months ago - PRNewsWire

Emmaus Life Sciences Announces Submission of Endari® Marketing Authorization Application in Kuwait

TORRANCE, Calif., July 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today t...

2 months ago - PRNewsWire

Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manag...

TORRANCE, Calif., June 15, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today i...

3 months ago - PRNewsWire

Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari® to the Saudi Food & Drug...

TORRANCE, Calif., May 26, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today th...

3 months ago - PRNewsWire

Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business Review

TORRANCE, Calif., May 4, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today its...

4 months ago - PRNewsWire

Emmaus Life Sciences Announces Informational Stockholders Meeting

--Meeting Will be Open to the Public-- --Meeting Will be Open to the Public--

1 year ago - GlobeNewsWire

UPDATE - Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug ...

TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi F...

1 year ago - GlobeNewsWire

Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority

TORRANCE, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi F...

1 year ago - GlobeNewsWire

Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial

--Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue-- TORRANCE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cel...

1 year ago - GlobeNewsWire

Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates

TORRANCE, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, provided today additional operational updates for the year ended...

1 year ago - GlobeNewsWire

Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari™

TORRANCE Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA) issued ...

1 year ago - GlobeNewsWire

Emmaus Life Sciences Accelerates Middle East and North Africa (MENA) Growth Strategy with Opening of its Dubai Office

TORRANCE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the opening of its regional office in Dubai. Th...

1 year ago - GlobeNewsWire

Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari® for Diverticulosis

TORRANCE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease   treatment, is pleased to announce that it has engaged Partner Internatio...

1 year ago - GlobeNewsWire

Emmaus Life Sciences to Restate Previously Issued Financial Statements

TORRANCE, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it will be restating its previously issued audi...

1 year ago - GlobeNewsWire

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Israeli Ministry of Health

TORRANCE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it was issued a license from the Israeli M...

1 year ago - GlobeNewsWire

National Institutes of Health Announces Intention with Respect to Grant of Exclusive Patent License to Emmaus Life Sc...

Patented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indications Patented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indications

1 year ago - GlobeNewsWire

Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?

Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.

1 year ago - Zacks Investment Research